Safety and Immunogenicity Study of SCB-1019T in Children
Phase 1
Withdrawn
- Conditions
- RSV Infection
- Interventions
- Biological: low dose SCB-1019TBiological: adjuvanted low dose SCB-1019TOther: PlaceboBiological: high dose SCB-1019TBiological: adjuvanted high dose SCB-1019T
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Target Recruit Count
- 112
- Registration Number
- NCT06666179
- Locations
- 🇦🇺
The Kids Research Institute, Perth, Western Australia, Australia
Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults
Phase 3
Withdrawn
- Conditions
- COVID-19
- Interventions
- Biological: SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19Biological: SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Registration Number
- NCT06567457
First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Vaccination
- Interventions
- Biological: Candidate vaccine, SCB-1019Biological: placeboBiological: candidate vaccine, SCB-1019T
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty
- Target Recruit Count
- 160
- Registration Number
- NCT06194318
- Locations
- 🇦🇺
Fusion Clinical Research, Adelaide, Southern Australia, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
Phase 3
Withdrawn
- Conditions
- COVID-19
- Interventions
- Biological: SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injectionBiological: SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Registration Number
- NCT05926440
- Locations
- 🇵🇭
Health Index Multispecialty Clinic, Manila, Philippines
🇵🇭Manila Doctors Hospital, Manila, Philippines
🇵🇭Tropical Disease Foundation, Putatan, Philippines
Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Candidate vaccine, SCB-2019Biological: Candidate vaccine, SCB-2020SOther: Squalene based adjuvantOther: CpG/alum adjuvant
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Target Recruit Count
- 153
- Registration Number
- NCT05228314
- Locations
- 🇿🇦
Josha Research, Bloemfontein, South Africa
🇿🇦Global Clinical Trials (Pty) Ltd, Pretoria, South Africa
🇿🇦Wits Vaccines and Infectious Diseases Analytics (VIDA) Research Unit, Soweto, South Africa
Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
Phase 2
Withdrawn
- Conditions
- COVID-19
- Interventions
- Biological: Candidate vaccine, SCB-2019
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Registration Number
- NCT05193279
- Locations
- 🇨🇴
Clínica de la Costa Ltda, Barranquilla, Colombia
🇨🇴Centro de Estudios en Infectología Pediátrica S.A.S. - CEIP S.A.S., Cali, Colombia
Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults
Phase 3
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Candidate vaccine, SCB-2019Biological: Vaxzevria VaccineBiological: CoronaVac VaccineBiological: Comirnaty Vaccine
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Target Recruit Count
- 1831
- Registration Number
- NCT05188677
- Locations
- 🇵🇭
Las Piñas Doctors Hospital, Las Piñas, Metro Manila, Philippines
🇵🇭Manila Doctors Hospital, Manila, Metro Manila, Philippines
Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases
Phase 3
Terminated
- Conditions
- COVID-19
- Interventions
- Biological: CpG 1018/Alum-adjuvanted SCB-2019 vaccineBiological: HavrixOther: Placebo; 0.9% saline
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Target Recruit Count
- 1
- Registration Number
- NCT05012787
- Locations
- 🇺🇦
Medical Centre of Edelweiss Medics LLC, Kyiv, Ukraine
🇺🇦Medical Center of Medbud-Clinic LLC, Kyiv, Ukraine
🇺🇦Center of Family Medicine Plus, LLC, Kyiv, Ukraine
Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults
Phase 2
Withdrawn
- Conditions
- COVID-19
- Interventions
- Biological: candidate vaccine, SCB-2020S
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Registration Number
- NCT04950751
Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: SCB-2019
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Target Recruit Count
- 137
- Registration Number
- NCT04932824
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Territory Western Australia, Australia